Notice of allowance for patent grant in Japan
Poolbeg Pharma PLC (AIM:PLOB) Immunomodulator I Patent Opposition Withdrawal
An important step in the continued protection of Poolbeg’s patent family
Poolbeg Pharma PLC (AIM:POLB) Interim results for the six months to 30 June 2023
Significant progress made and well positioned for future growth
hVIVO PLC (AIM:HVO) Interim results
Strong first-half performance and record forward visibility Upgrade of Full Year Revenue and EBITDA Guidance
hVIVO PLC (AIM:HVO) Plans for a new larger state-of-the-art facility
Plans for a new larger state-of-the-art facility to meet growing demand
hVIVO PLC (AIM:HVO) Notice of Results
hVIVO plc (AIM & Euronext: HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that it will release its interim results for
hVIVO PLC (AIM & Euronext: HVO) Trading update
Strong first-half performance and record order book On track to deliver full-year guidance and long-term sustainable growth
hVIVO PLC (AIM:HVO) Flu B challenge model
£13.1m contract with the global pharmaceutical client to develop an influenza B virus challenge model
Poolbeg Pharma PLC (AIM:POLB) AI led programme identifies influenza drug targets
Successful Artificial Intelligence led programme identifies multiple influenza drug targets
hVIVO PLC (AIM:HVO) hMPV human challenge model
hVIVO to develop human metapneumovirus (hMPV) challenge model First client of the new hMPV model secured
Poolbeg Pharma PLC (AIM:POLB) Oral Vaccine Programme Moves Forward
Next-Generation Oral Vaccine Programme Advancing Through Non-Dilutive Funding